Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Fineline Cube Jul 2, 2026
Company Drug

Abbisko Therapeutics and X4 Pharmaceuticals Announce Positive Phase III Results for Mavorixafor in WHIM Syndrome

Fineline Cube May 19, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) and its US partner X4 Pharmaceuticals Inc....

Company Deals

Shenzhen Kangtai Biological Partners with Saudi Importer for Pneumonia Vaccine Distribution

Fineline Cube May 19, 2023

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced a strategic partnership with...

Company Drug

FibroGen’s Roxadustat Shows Positive Results in Phase III Chemotherapy-Induced Anemia Trial

Fineline Cube May 19, 2023

US-based FibroGen Inc. (NASDAQ: FGEN) has announced positive topline data from a Phase III trial...

Company

GenScipt Biotech Corp. Expands Oligonucleotide and Peptide Manufacturing in Zhenjiang

Fineline Cube May 19, 2023

China-based Contract Development and Manufacturing Organization (CDMO) GenScipt Biotech Corp. (HKG: 1548) has revealed the...

Company Drug

NMPA Approves Nanjing Sanhome’s Alfosbuvir for Chronic Hepatitis C Treatment

Fineline Cube May 18, 2023

Nanjing Sanhome Pharmaceutical Co., Ltd has announced that its Category 1 drug alfosbuvir has been...

Company Drug

Betta Pharmaceuticals Initiates Phase I/II Study for First-In-Class BsAb BPB-101

Fineline Cube May 18, 2023

China’s Betta Pharmaceuticals (SHE: 300558) has announced the enrollment of the first patient in a...

Company Drug

Antengene’s First-in-Class CD24 mAb ATG-031 Gets US FDA Approval for Phase I Study

Fineline Cube May 18, 2023

Antengene Corp., Ltd (HKG: 6996) has announced that it has received approval from the US...

Company Drug

BioRay Pharmaceutical’s Zuberitamab Approved by NMPA for CD20 Positive DLBCL Treatment

Fineline Cube May 18, 2023

BioRay Pharmaceutical Co., Ltd has announced that its drug zuberitamab has been approved by the...

Company Drug

WestVac Biopharma Receives FDA Approval for COVID-19 Protein Vaccines Targeting XBB Variants

Fineline Cube May 18, 2023

Chengdu-based WestVac Biopharma Co., Ltd has announced receiving clinical trial approval from the National Medical...

Company Drug

CARSgen Therapeutics Initiates Phase II Study for CT041 in Advanced Gastric Cancer

Fineline Cube May 18, 2023

China-based chimeric antigen receptor (CAR)-T cell specialist CARSgen Therapeutics Holdings Ltd (HKG: 2171) has announced...

Company Deals

National Vaccine & Serum Institute Partners with Corning Life Sciences to Foster Innovation

Fineline Cube May 18, 2023

The National Vaccine & Serum Institute has announced a partnership with Corning Life Sciences, aiming...

Company Drug

CDE Lists Three Home-Grown Drugs for Priority Review, Including Myopia Treatment

Fineline Cube May 18, 2023

The Center for Drug Evaluation (CDE) website has indicated that three home-grown drugs are on...

Company Medical Device

Grand Pharmaceutical’s Novasight Hybrid System Receives Marketing Approval in China

Fineline Cube May 18, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its Novasight Hybrid System, a...

Company Deals

HitGen Inc. Enters Research Agreement with ARase Therapeutics to Discover Oncology Inhibitors

Fineline Cube May 18, 2023

China-based HitGen Inc. (SHA: 688222) has announced a research agreement with ARase Therapeutics, Inc. Under...

Company Deals Drug

BeiGene and The Max Foundation Collaborate to Expand Access to Brukinsa for CLL Patients

Fineline Cube May 18, 2023

China-based biotech BeiGene (NASDAQ: BGNE) has formed a collaboration with US-based non-profit organization The Max...

Company Drug

Huadong Medicine’s HDM1002 Receives NMPA Approval for Type 2 Diabetes Clinical Trial

Fineline Cube May 18, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving clinical trial approval from the...

Company Drug

Everest Medicines Completes Patient Enrollment in Etrasimod Phase III UC Trial

Fineline Cube May 17, 2023

Everest Medicines (HKG: 1952), a China-based biopharmaceutical company, has declared the successful completion of patient...

Company Legal / IP R&D

HuidaGene Secures US Patent for High-Efficiency Cas12Max DNA Editing System

Fineline Cube May 17, 2023

HuidaGene Therapeutics, a China-based biotechnology company, has announced the receipt of patent protection from the...

Company Drug

Jiangsu Hengrui’s SHR0302 Secures Clinical Trial Approval for GVHD Treatment

Fineline Cube May 17, 2023

Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading China-based pharmaceutical company, has announced the receipt of...

Company Drug

Sanofi’s VaxigripTetra Expands Influenza Vaccine Access to All Ages in China

Fineline Cube May 17, 2023

French pharmaceutical company Sanofi (NASDAQ: SNY) has announced that its tetravalent influenza virus split vaccine,...

Posts pagination

1 … 548 549 550 … 690

Recent updates

  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
  • TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations
  • TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Company Drug

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.